Royal Bank of Canada Upgrades Hikma Pharmaceuticals (OTCMKTS:HKMPF) to Moderate Buy

Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by equities research analysts at Royal Bank of Canada from a “hold” rating to a “moderate buy” rating in a report released on Tuesday,Zacks.com reports.

Hikma Pharmaceuticals Stock Performance

OTCMKTS:HKMPF opened at $24.87 on Tuesday. The stock has a fifty day simple moving average of $24.48 and a 200 day simple moving average of $24.92. Hikma Pharmaceuticals has a 1-year low of $21.90 and a 1-year high of $26.50. The company has a current ratio of 1.66, a quick ratio of 0.98 and a debt-to-equity ratio of 0.46.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.